Rationale and Objectives Despite all the benefits and effectiveness of the coronavirus disease 2019 (COVID-19) vaccines mentioned in recent clinical trials, some post-vaccination side effects such as lymphadenopathy (LAP) were observed. The present study reviewed all studies with imaging findings presentation of LAP after COVID-19 vaccination. Materials and Methods We conducted a literature search in online databases, including Scopus, Medline (PubMed), Web of Science, Embase (Elsevier), Cochrane library, and Google Scholar. Results A total of 19 studies (68 cases), including 60 (88.2%) females and eight (11.8%) males with a presentation of LAP after COVID-19 vaccination, were reviewed. LAP was identified after first or second dosages of three types of COVID-19 vaccines, including Pfizer-BioNTech ( n = 30, 44.1%), Moderna ( n = 17, 25%), and Oxford-AstraZeneca ( n = 1, 1.5%). In 20 (29.4%) cases, vaccine type was not reported or only reported as mRNA COVID-19 vaccine. The median days of LAP presentation after the first and second dosages of COVID-19 vaccination, were 12 and 5 days, respectively. Most of the LAP imaging findings related to COVID-19 vaccination ( n = 66, 97%) were seen from first day to 4 weeks after vaccination. However, LAP remained after 5 and 6 weeks of the first and second dosages of COVID-19 vaccination with decreased lymph nodes’ size and residual cortical thickening in two cases. Conclusion This review study of cases with LAP-associated COVID-19 vaccination guides radiologists and physicians to rely on patient’s clinical context and updated resources to prevent potential disease upstaging and change in therapy.
【저자키워드】 SARS-CoV-2, coronavirus, vaccination, COVID-19, Coronavirus disease 2019, radiology, Pfizer-BioNTech, Moderna, Oxford-AstraZeneca, CDC, Centers for Disease Control and Prevention, FDA, Food and Drug Administration, EUA, Emergency Use Authorization, Adenopathy, LAP, Lymphadenopathy, LN, Lymph node, BC, Breast cancer, BIRADS, Breast Imaging Reporting and Data System,